Oncolytic Virus Therapy Market Analysis

  • Report ID: 2988
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Oncolytic Virus Therapy Market Analysis

Therapy Type (HSV-based, Adenovirus-based, Reovirus, Poxviruses, NDV)

The HSV-based oncolytic virus therapy market is estimated to gain a robust revenue share of about 30% in the coming years owing to the large number of clinical trials ongoing related to HSV-based viruses. For instance, HSV has two existing variants:  HSV Type 1 (HSV-1) and HSV Type 2 (HSV-2). Among these two existing variants HSV-1 has been widely investigated in cancer oncolytic viral therapy. Approximately, 58% of the U.S. population and around 67% of the global population have evidence of exposure to HSV-1 at the same point during their lifetime. Furthermore, genomic manipulation, cytotoxicity, pathogenicity, and the availability of antiviral drugs have resulted in the growing demand for oncolytic HSV-1 widely as a therapeutic approach to melanoma.

End-User (Hospitals, Specialty Clinics, Cancer Research Institutes)

The hospitals segment in the oncolytic virus therapy market is set to garner a notable share in near future as most of the patients approach these facilities for the treatment. Patients with diseases such as cancer, when receiving an early diagnosis in hospitals, their survival rate and chances for successful treatment increase significantly. Within the hospital premises round the clock healthcare professionals including medical oncologists, and other specialists are available to help patients with cancer in the treatment planning.

Our in-depth analysis of the global market includes the following segments:

Therapy Type

  • HSV-based
  • Adenovirus-based
  • Reovirus
  • Poxviruses
  • NDV

Virus Type

  • Oncolytic Wild
  • Genetically Engineered

Indication

  • Head & Neck
  • Lung
  •  Kidney
  •  Liver
  • Pancreatic
  • Breast
  • Colorectal
  • Sarcoma
  • Bone Cancer
  • Angiosarcoma
  • Fibrosarcoma
  • Leiomyosarcoma
  • Melanoma

Demography

  • Adults
  • Pediatric

End-User

  • Hospitals
  • Specialty Clinics
  • Cancer Research Institutes
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 2988
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of oncolytic virus therapy is evaluated at USD 27.99 million.

The oncolytic virus therapy market size was valued at USD 23.09 million in 2024 and is expected to reach USD 490.46 million by 2037, registering around 26.5% CAGR during the forecast period i.e., between 2025-2037. Increasing prevalence of cancer globally and the growing advancements in viral engineering will drive the market growth.

North America industry is predicted to dominate majority revenue share of 39% by 2037, impelled by growing clinical activities in the region.

The major players in the market include Amgen Inc., Shanghai Sunway Biotech Co. Ltd., Oncolys BioPharma Inc., TILT Biotherapeutics Ltd., Oncorus Inc, TAKARA BIO INC., Vyriad, Transgene SA, Lokon Pharma AB, Pfizer, Inc., Rigvir Group, Sibiono GeneTech Co. Ltd., Oncolytics Biotech, Daiichi Sankyo, Kissei Pharmaceutical Co., Ltd., Boehringer Ingelheim
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample